CD8A and melanoma: These observations suggest the preexisting host immune cell repertoire associated with HG-T status, which we validated in an independent cohort of patients with melanoma from the CM-915 trial, identifies patients belonging to HG-T as having a reduced proportion of baseline peripheral CD8+ effectors T cells.